![Show Menu](styles/mobile-menu.png)
![Page Background](./../common/page-substrates/page0892.png)
/
/
SBRT for prostate cancer
Matthias Guckenberger - DEGRO 2015
3
Why SBRT
Why not SBRT
Small well circumscribed target
Risk of extracapsular extension
Low alpha / beta ratio
Really very low
Benefit of dose escalation
Only for bRFS
Technical solutions available
Lack of standardization
Strong competition
Should not be a reason per se
13.06.2016